Niaspan Reverse Payment Antitrust Litigation

Court: United States District Court, Eastern District of Pennsylvania

Case No.: 13-md-2460

Leadership Position: Interim Co-Lead Counsel

WBE is Interim Co-Lead Counsel for the end purchaser plaintiffs in an antitrust class action against AbbVie Inc. and Teva Pharmaceuticals USA, Inc. (and related companies) involving the cholesterol drug Niaspan.  The plaintiffs allege that the defendants conspired to keep a generic version of Niaspan off the market for more than eight years.  The plaintiffs have also alleged that the defendants’ conduct caused consumers and drug benefit plans to pay more for Niaspan and its generic equivalents than they otherwise would have, in violation of state antitrust and consumer protection laws.

To view a copy of the consolidated class action complaint, click here.

News Articles

Plaintiffs Largely Defeat Motion to Dismiss in RICO Lawsuit Against Centene Corporation, Alleging that Centene Defrauds Consumers through Sale of Its Ambetter Health Insurance Plans

On Thursday, May 2, 2024, U.S. District Court Judge Nancy L. Maldonado ruled that Plaintiffs in Havrilla v. Centene Corp. (N.D. Ill.) could proceed on the majority of their claims against ...

WBE Attorneys Named Among Law360 Legal Lions of the Week

WBE attorneys were honored alongside peers and co-counsel this week, as Law360 recognized the firm for successfully defeating motions to dismiss by John Deere in the publication’s Legal Lions of ...

WBE Appointed Interim Co-Lead Counsel in Amazon Tying Scheme Antitrust Lawsuit

On Monday, November 27 2023, U.S. District Judge John H. Chun of the Western District of Washington appointed attorneys from WBE to serve as interim co-lead counsel and consolidated two proposed ...